Phase II trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

Protocol No
HCRN-GU19-385-PLANE-PC
Phase
II
Summary

This project is being done to test the good and bad effects of giving Pembrolizumab and Lenvatinib for metastatic (advanced) neuroendocrine prostate cancer.

Description
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL